← Back to All Filings

Boston Scientific Discloses Material Financial Impact & Guidance Risk from Cybersecurity Incident

High SignificanceSeptember 8, 2026 at 7:07:14 AM EDT

BOSTON SCIENTIFIC CORP

$BSX8-KCIK: 0000885725

Subscribe to track BSX

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Boston Scientific (NYSE: BSX) filed Form 8-K (Item 1.05) regarding its ongoing response to a cybersecurity incident identified on August 25, 2026.\n\nKey Highlights:\n- Financial Guidance Impact: The incident is determined likely to have a material impact on Q3 and FY 2026 operating results; the company stated it is unlikely to meet previously issued Q3 and FY 2026 net sales growth and adjusted EPS guidance.\n- Operational Status: Distribution network substantially restored; sterilization and manufacturing operations have resumed across most global facilities.\n- Long-Term Outlook: No material impact expected on long-term financial condition.\n- Next Update: Full updated outlook will be provided on the Q3 2026 earnings call on October 28, 2026.

Comprehensive Analysis

Item 1.05 Material Cybersecurity Incident Update

Boston Scientific Corporation (NYSE: BSX) has provided a material update on the cybersecurity incident originally identified on August 25, 2026.

Key Findings & Operational Updates

  • Unauthorized Activity: The incident involved unauthorized activity leading to a network outage affecting operating systems and business applications, disrupting manufacturing and order shipments.
  • Containment & Restoration: As of September 7, 2026, no evidence of ongoing unauthorized access has been identified. Distribution networks are substantially restored, sterilization facilities are operational, and global manufacturing has resumed across most facilities.

Financial & Guidance Impact

  • Material Operating Impact: The company determined the disruption will likely have a material impact on results of operations for both the third quarter and full year 2026.
  • Guidance Withdrawn/Unlikely to Meet: Boston Scientific stated it is unlikely to achieve its previously issued Q3 and full-year 2026 net sales growth and adjusted EPS guidance (originally provided July 29, 2026).
  • Long-Term Financial Condition: The incident is not expected to materially impact long-term financial health.
  • Upcoming Outlook: A revised financial outlook will be provided during the Q3 2026 earnings call scheduled for October 28, 2026.
Topics:#BSX#Cybersecurity#GuidanceUpdate#SEC#MedTech

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.